TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07718737: Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Pro

Sponsor: Multitude Therapeutics Inc. · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 512 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT07718737 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07718737 Rescue Dossier →